{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:48Z","timestamp":1792790448640,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12519-019-00285-9","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:07:12Z","timestamp":1563966432000},"page":"546-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies"],"prefix":"10.1007","volume":"15","author":[{"given":"Hao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Lai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"285_CR1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/bjd.12804","volume":"170","author":"A Munden","year":"2014","unstructured":"Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170:907\u201313.","journal-title":"Br J Dermatol."},{"key":"285_CR2","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","volume":"136","author":"DH Darrow","year":"2015","unstructured":"Darrow DH, Greene AK, Mancini AJ, Nopper AJ, Section on Dermatology, Section on Otolaryngology-Head, and Neck Surgery, and Section on Plastic Surgery. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136:e1060\u2013104.","journal-title":"Pediatrics"},{"key":"285_CR3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm.1877","volume":"14","author":"M Jinnin","year":"2008","unstructured":"Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomas. Nat Med. 2008;14:1236\u201346.","journal-title":"Nat Med."},{"key":"285_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00431-014-2403-6","volume":"174","author":"SR Janmohamed","year":"2015","unstructured":"Janmohamed SR, Madern GC, de Laat PC, Oranje AP. Educational paper: pathogenesis of infantile haemangioma, an update 2014 (part I). Eur J Pediatr. 2015;174:97\u2013103.","journal-title":"Eur J Pediatr."},{"key":"285_CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM199907153410307","volume":"341","author":"BA Drolet","year":"1999","unstructured":"Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173\u201381.","journal-title":"N Engl J Med."},{"key":"285_CR6","doi-asserted-by":"crossref","first-page":"F85","DOI":"10.1136\/archdischild-2014-306197","volume":"100","author":"R Goelz","year":"2015","unstructured":"Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015;100:F85\u201391.","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"285_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpeds.2006.12.003","volume":"150","author":"AN Haggstrom","year":"2007","unstructured":"Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150:291\u20134.","journal-title":"J Pediatr."},{"key":"285_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390:85\u201394.","journal-title":"Lancet"},{"key":"285_CR9","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649\u201351.","journal-title":"N Engl J Med."},{"key":"285_CR10","doi-asserted-by":"crossref","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","volume":"143","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143:e20183475.","journal-title":"Pediatrics"},{"key":"285_CR11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735\u201346.","journal-title":"N Engl J Med."},{"key":"285_CR12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2014.01.905","volume":"70","author":"A \u00c1barz\u00faa-Araya","year":"2014","unstructured":"\u00c1barz\u00faa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014;70:1045\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"285_CR13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.bjoms.2015.09.005","volume":"53","author":"H Gong","year":"2015","unstructured":"Gong H, Xu DP, Li YX, Cheng C, Li G, Wang XK. Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. Br J Oral Maxillofac Surg. 2015;53:836\u201340.","journal-title":"Br J Oral Maxillofac Surg."},{"key":"285_CR14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamadermatol.2017.0250","volume":"153","author":"KH Kim","year":"2017","unstructured":"Kim KH, Choi TH, Choi Y, Park Y, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153:529\u201336.","journal-title":"JAMA Dermatol."},{"key":"285_CR15","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jpedsurg.2013.08.020","volume":"48","author":"MA Malik","year":"2013","unstructured":"Malik MA, Menon P, Rao KLN, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg. 2013;48:2453\u20139.","journal-title":"J Pediatr Surg."},{"key":"285_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/JCRS.JCRS_1_17","volume":"22","author":"AK Mona","year":"2016","unstructured":"Mona AK, Ayman MF. \u03b2-Blocker versus triamacinolone acetate in the treatment of infantile periocular hemangioma. Egypt J Cataract Refract. 2016;22:42\u20139.","journal-title":"Egypt J Cataract Refract."},{"key":"285_CR17","first-page":"164","volume":"28","author":"M Tan","year":"2012","unstructured":"Tan M, Duan B, Zhou CM, Gong H. The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke Za Zhi. 2012;28:164\u20138 (in Chinese).","journal-title":"Zhonghua Zheng Xing Wai Ke Za Zhi."},{"key":"285_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.XPS.0000482654.21247.63","volume":"13","author":"SM Abdel Wahab","year":"2017","unstructured":"Abdel Wahab SM, Almetaher HA, Fayad H, Elhalaby E. Oral versus topical propranolol for management of superficial infantile hemangiomas: a comparative study. Ann Pediatr Surg. 2017;13:1\u20137.","journal-title":"Ann Pediatr Surg."},{"key":"285_CR19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1684\/ejd.2013.2146","volume":"23","author":"H Zaher","year":"2013","unstructured":"Zaher H, Rasheed H, Esmat S, Hegazy RA, Gawdat HI, Hegazy RA, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013;23:646\u201352.","journal-title":"Eur J Dermatol."},{"key":"285_CR20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2015.09.061","volume":"74","author":"H Zaher","year":"2016","unstructured":"Zaher H, Rasheed H, El-Komy MM, Hegazy RA, Gawdat HI, Abdel Halim DM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomizedcontrolled trial. J Am Acad Dermatol. 2016;74:499\u2013505.","journal-title":"J Am Acad Dermatol."},{"key":"285_CR21","first-page":"16","volume":"7","author":"A Ali","year":"2018","unstructured":"Ali A, Aiman U, Haseen MA, Mir MA, Ghani I, Bharadwaj R, et al. The effect of oral propranolol versus oral corticosteroids in management of pediatric hemangiomas. World J Plast Surg. 2018;7:16\u201324.","journal-title":"World J Plast Surg."},{"key":"285_CR22","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.bjps.2013.07.035","volume":"66","author":"M de Graaf","year":"2013","unstructured":"de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijinzeel-Koomen CA, Kon M, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013;66:1732\u201340.","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"285_CR23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MPH.0b013e3182a11658","volume":"35","author":"V Sondhi","year":"2013","unstructured":"Sondhi V, Patnaik SK. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J Pediattr Hemantol Oncol. 2013;35:493\u20139.","journal-title":"J Pediattr Hemantol Oncol."},{"key":"285_CR24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","volume":"147","author":"CJ Price","year":"2011","unstructured":"Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147:1371\u20136.","journal-title":"Arch Dermatol."},{"key":"285_CR25","doi-asserted-by":"crossref","first-page":"733e","DOI":"10.1097\/PRS.0b013e318245e739","volume":"129","author":"PK Thayal","year":"2012","unstructured":"Thayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012;129:733e\u20135e.","journal-title":"Plast Reconstr Surg."},{"key":"285_CR26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fonc.2018.00605","volume":"8","author":"HW Wu","year":"2018","unstructured":"Wu HW, Wang X, Zhang L, Zheng JW, Liu C, Wang YA. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol. 2018;8:605.","journal-title":"Front Oncol."},{"key":"285_CR27","first-page":"962","volume":"7","author":"SM Yuan","year":"2014","unstructured":"Yuan SM, Cui L, Guo Y, Xue CY, Hong ZJ, Jiang HQ. Management of periorbital hemangioma by intralesional glucocorticoids and systemic propranolol: a single-center retrospective study. Int J Clin Exp Med. 2014;7:962\u20137.","journal-title":"Int J Clin Exp Med."},{"key":"285_CR28","doi-asserted-by":"crossref","first-page":"21670","DOI":"10.1038\/srep21670","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang L, Yuan WE, Zheng JW. Pharmacological therapies for infantile hemangiomas: a clinical study in 853 consecutive patients using a standard treatment algorithm. Sci Rep. 2016;6:21670.","journal-title":"Sci Rep."},{"key":"285_CR29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/lary.20633","volume":"119","author":"L Buckmiller","year":"2009","unstructured":"Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119:2051\u20134.","journal-title":"Laryngoscope."},{"key":"285_CR30","doi-asserted-by":"crossref","first-page":"e0138100","DOI":"10.1371\/journal.pone.0138100","volume":"10","author":"X Liu","year":"2015","unstructured":"Liu X, Qu X, Zheng J, Zhang L. Effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas: a meta-analysis. PLoS ONE. 2015;10:e0138100.","journal-title":"PLoS ONE"},{"key":"285_CR31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cbi.2018.08.018","volume":"294","author":"B Sun","year":"2018","unstructured":"Sun B, Dong C, Lei H, Gong Y, Li M, Zhang Y, et al. Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4\/Notch1\/Akt pathway. Chem Biol Interact. 2018;294:28\u201333.","journal-title":"Chem Biol Interact."},{"key":"285_CR32","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1002\/jcb.27957","volume":"120","author":"F Zhao","year":"2019","unstructured":"Zhao F, Yang X, Xu G, Bi J, Lv R, Huo R. Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295. J Cell Biochem. 2019;120:6614\u201323.","journal-title":"J Cell Biochem."},{"key":"285_CR33","first-page":"684","volume":"18","author":"TH Yao","year":"2018","unstructured":"Yao TH, Pataer P, Regmi KP, Gu XW, Li QY, Du JT, et al. Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway. Mol Med Rep. 2018;18:684\u201394.","journal-title":"Mol Med Rep."},{"key":"285_CR34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","volume":"163","author":"CH Storch","year":"2010","unstructured":"Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269\u201374.","journal-title":"Br J Dermatol."},{"key":"285_CR35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/pr.2017.93","volume":"82","author":"JR Dornhoffer","year":"2017","unstructured":"Dornhoffer JR, Wei T, Zhang H, Miller E, Cleves MA, Richter GT. The expression of renin-angiotensin-aldosterone axis components in infantile hemangioma tissue and the impact of propranolol treatment. Pediatr Res. 2017;82:155\u201363.","journal-title":"Pediatr Res."},{"key":"285_CR36","doi-asserted-by":"crossref","first-page":"e6138","DOI":"10.1590\/1414-431x20176138","volume":"50","author":"YZ Chen","year":"2017","unstructured":"Chen YZ, Bai N, Bi JH, Liu XW, Xu GQ, Zhang LF, et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1\u03b1 dependent mechanisms. Braz J Med Biol Res. 2017;50:e6138.","journal-title":"Braz J Med Biol Res."},{"key":"285_CR37","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/pbc.25453","volume":"62","author":"WK Pan","year":"2015","unstructured":"Pan WK, Li P, Guo ZT, Huang Q, Gao Y. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K\/Akt\/eNOS\/VEGF pathway. Pediatr Blood Cancer. 2015;62:1414\u201320.","journal-title":"Pediatr Blood Cancer."},{"key":"285_CR38","doi-asserted-by":"crossref","first-page":"e20153896","DOI":"10.1542\/peds.2015-3896","volume":"137","author":"S Chinnadurai","year":"2016","unstructured":"Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. Pharmacologic interventions for infantile hemangioma: a meta-analysis. Pediatrics. 2016;137:e20153896.","journal-title":"Pediatrics"},{"key":"285_CR39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bcp.12235","volume":"78","author":"Y Lou","year":"2014","unstructured":"Lou Y, Peng WJ, Cao Y, Cao DS, Xie J, Li HH. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78:44\u201357.","journal-title":"Br J Clin Pharmacol."},{"key":"285_CR40","doi-asserted-by":"crossref","first-page":"e20160353","DOI":"10.1542\/peds.2016-0353","volume":"138","author":"C L\u00e9aute-Labr\u00e8ze","year":"2016","unstructured":"L\u00e9aute-Labr\u00e8ze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebb\u00e9 G, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138:e20160353.","journal-title":"Pediatrics"},{"key":"285_CR41","first-page":"CD006545","volume":"4","author":"M Novoa","year":"2018","unstructured":"Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, et al. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 2018;4:CD006545.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12519-019-00285-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:33:23Z","timestamp":1595460803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12519-019-00285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s12519-019-00285-9","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests. No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}